According to incomplete statistics from the People's Daily health client, this week (April 15-April 19), a total of 10 companies in the national medical and health field have received investment and financing. Among them, Binhui Biotechnology, Shenluo Medical, and Microvision Imaging have raised more than 100 million yuan. On the whole, the financing companies involve innovative biomedicine, cell and gene therapy, neuroimplantable medical devices, ophthalmic intelligent diagnosis and treatment equipment and other fields.
Biopharmaceuticals
Shenzhen Cell Valley: Completed nearly 100 million yuan angel + Pre-A round of capital increase and share expansion
On April 18, Shenzhen Cell Valley successfully completed nearly 100 million yuan of angel + Pre-A round of capital increase and share expansion. The main purpose of this capital increase and share expansion is to expand the company's business scale and improve the company's profitability and market competitiveness.
Shenzhen Cell Valley is a one-stop integrated outsourcing service provider focusing on the cell and gene therapy industry, which was co-founded by returnee scientists from Harvard University and the University of California, San Diego. Shenzhen Cell Valley is a major public service platform for Shenzhen's biomedical industry and a research platform for viral vector common technology of the National Engineering Research Center for key common technologies in the cell industry.
Shenzhen Cell Valley R&D personnel are working. Shenzhen Cell Valley official website map
Xitong Bio: Received nearly 10 million yuan in seed round financing
On April 18, Xitong Biotechnology Co., Ltd. announced that it had successfully obtained a seed round of financing of nearly 10 million yuan, which was led by Suzhou Shishangbai Venture Partnership.
Xitong Biotech is a developer of biomedical tools, committed to the development of innovative biomedical tools. The company was established on July 10, 2023 to solve the current problems of low repeatability and reliability at the R&D end and the unsmooth technical docking between research results and industrialization.
Binhui Bio: Obtained hundreds of millions of yuan in Series C financing
On April 17, Binhui Biotech completed hundreds of millions of yuan in Series C financing, with investors including Zhongbo Juli.
Founded by Dr. Binlei Liu, a key member of the original research team of the approved oncolytic virus T-VEC (Imlygic), the main product is recombinant oncolytic II herpes simplex virus (OH2) injection, which is suitable for lung cancer, head and neck tumors, lymphoma, liver cancer, melanoma and other diseases, and can also be used in combination with traditional chemoradiotherapy, aiming to improve the efficacy and reduce side effects for users.
Yizun Biotech: Completed nearly 100 million yuan in Series A+ financing
On April 15, Yizun Biotech announced the completion of nearly 100 million yuan in Series A+ financing, which was jointly led by Tailong Investment and Taiyu Investment. This round of financing will help Yizun Pharma accelerate the R&D and services of innovative biopharmaceuticals.
Founded in 2017, Yizun Pharma is a R&D company focusing on the field of biomedicine, with a variety of cell therapy technologies, including CAR-T/TCR-T cell technology for tumors. The company is committed to providing patients with more effective and safe treatment options and promoting technological innovation in the field of biomedicine.
Medical devices
Shenluo Medical: Obtained hundreds of millions of yuan in B+ round financing
On April 18, Shenluo Medical announced that it had received hundreds of millions of yuan in Series B+ financing. The round of financing was led by OrbiMed Capital, followed by the old shareholder Boyuan Capital. This round of financing will be mainly used for new product research and development, clinical research, registration application, core technology iteration and commercial expansion of Shenluo Medical.
As a neuromodulation platform company, Shenluo Medical is committed to the independent R&D and production of medical devices in the field of implantable neurostimulation and brain-computer interface, with the goal of continuously providing patients with inclusive neuromodulation therapy products.
Zhiqin Instrument: Completed tens of millions of yuan in A+ round of financing
On April 15, Zhiqin Instrument completed tens of millions of yuan in A+ round of financing, and the funds raised in this round will be used for investment in Zhiqin headquarters, R&D, and production base construction.
Founded in 2018, Zhiqin Instrument focuses on self-developed sampling systems, ion sources, mass analyzers, detectors and data systems, develops small, portable and large-scale mass spectrometer products, and is committed to providing customers with a full range of solutions for analysis and testing, so as to continue to help users in food safety, medical health and other fields obtain suitable testing instruments.
Ruimeng Medical: Completed tens of millions of yuan in Series A financing
On April 15, Ruimeng Medical announced the completion of tens of millions of yuan in Series A financing, which was led by Zijingang Capital and followed by industrial capital such as Haoyiduo. The financing funds are mainly used to increase R&D investment and the construction of automated production lines.
Founded in September 2019, Ruimeng Medical brings together veterans in the fields of medical devices, health management, mobile Internet, and big data processing to create a new form of medical device R&D and production enterprises, committed to the development and production of PHIS small particle units (professional, wearable, implantable), new medical device Internet of Things products and professional intelligent services for disease management.
Medical services
Xinyi Biotech: Completed nearly 100 million yuan in Series B+ financing
On April 18, following the successful completion of the B+ round of financing of nearly 100 million yuan jointly invested by Shengdi Investment, Eli Lilly Asia Ventures and Jiuzhi Capital, Xinyi Biotech received another 100 million yuan investment from Beijing Pharmaceutical Fund. It is reported that this round of financing will be used to accelerate the clinical registration of the company's digital PCR and molecular POCT series reagent products, and promote the company's high-quality development and new business development.
Founded in October 2015, Beijing Xinyi Biotechnology Co., Ltd. has a high-level R&D team in the fields of instruments, chips, materials, reagents, software, etc., and has applied for more than 200 domestic and foreign patents and more than 100 authorized patents.
Seal Biology: Completed tens of millions of yuan in seed round financing
On April 16, the industry's leading gene editing company, Seal Code Biotech, completed a seed round of financing of tens of millions of yuan, which was exclusively led by Mifang Health Fund. The funds raised in this round of financing will be mainly used for the development and promotion of gene editing pipelines and the construction of ultra-small editor platforms.
Founded in 2023, SealCode Biotech is committed to transforming the clinical transformation of efficient ultra-small gene editors into gene drugs that can be "cured for life after one administration". The company has the world's leading ultra-small and efficient gene editor alphaCas, a metagenomic-based gene editor mining platform, and has the engineering capabilities of ultra-small gene editors and rapid target screening and pipeline development capabilities.
Vision Imaging: Completed the D round of financing of over 100 million yuan
On April 15, Vision Micro Imaging announced the completion of the D round of financing, with a financing amount of more than 100 million yuan, and the institutions participating in the investment include Haitong Kaiyuan.
Vision Image was founded in 2014 in Silicon Valley, USA. In 2015, with the support of the national industrial policy, the company's headquarters moved to China, and currently has three R&D centers in Silicon Valley, Shanghai and Luoyang.